The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation
Open accessAbstract
Cytomegalovirus (CMV) surveillance and preemptive therapy is the most commonly used strategy for CMV disease prevention in hematopoietic cell transplantation recipients. In 2007, we introduced a CMV prevention strategy for patients at risk for CMV disease using quantitative PCR surveillance, with treatment thresholds determined by patient risk factors. Patients (N = 367) received preemptive therapy either at a plasma viral load of ≥500 copies/mL, at ≥100 copies/mL if receiving ≥1 mg/kg of prednisone or anti-T cell therapies, or if a ≥5-fold viral load increase from baseline was detected. Compared with patients before 2007 undergoing antigenemia-based surveillance (n = 690) with preemptive therapy initiated for any positive level, the risk-adapted PCR-based strategy resulted in similar use of antiviral agents, and similar risks of CMV disease, toxicity, and nonrelapse mortality in multivariable models. The cumulative incidence of CMV disease by day 100 was 5.2% in the PCR group compared with 5.8% in the antigenemia group (1 year: 9.1% PCR vs 9.6% antigenemia). Breakthrough CMV disease in the PCR group was predominantly in the gastrointestinal (GI) tract (15 of 19 cases; 79%). However, unlike CMV pneumonia, CMV GI disease was not associated with increased nonrelapse mortality (adjusted hazard ratio, 1.19; P = .70 [GI disease] vs 8.18; P < .001 [pneumonia]). Thus, the transition to a preemptive therapy strategy based on CMV viral load and host risk factors successfully prevented CMV disease without increasing the proportion of patients receiving preemptive therapy and attributable toxicity. Breakthrough disease in PCR-based preemptive therapy occurs at a low incidence and presents primarily as GI disease, which is more likely to be responsive to antiviral therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Cited by
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Marty, F. M., Ljungman, P., Chemaly, R. F., Maertens, J., Dadwal, S. S., Duarte, R. F., Haider, S., Ullmann, A. J., Katayama, Y., Brown, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706640 · Cited by 1,238
Self-citationGreen, M. L., Leisenring, W., Xie, H., Mast, T. C., Cui, Y., Sandmaier, B. M., Sorror, M. L., Goyal, S., Özkök, S., Yi, J., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00289-6 · Cited by 419
Self-citationCMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
Marty, F. M., Winston, D. J., Rowley, S. D., Vance, E., Papanicolaou, G. A., Mullane, K. M., Brundage, T. M., Robertson, A. T., Godkin, S., Momméja-Marin, H., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303688 · Cited by 374
Self-citationGreen, M. L., Leisenring, W. M., Xie, H., Walter, R. B., Mielcarek, M., Sandmaier, B. M., Riddell, S. R., & Boeckh, M. (2013) · Blood · doi:10.1182/blood-2013-02-487074 · Cited by 313
Self-citationOutcomes of acute leukemia patients transplanted with naive T cell–depleted stem cell grafts
Bleakley, M., Heimfeld, S., Loeb, K. R., Jones, L. A., Chaney, C., Seropian, S., Gooley, T. A., Sommermeyer, F., Riddell, S. R., & Shlomchik, W. D. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81229 · Cited by 268
Metadata
- Authors
- Green, M. L., Leisenring, W., Stachel, D., Pergam, S. A., Sandmaier, B. M., Wald, A., Corey, L., & Boeckh, M.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 18
- Issue
- 11
- Pages
- 1687-1699
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2096698843
- Cited by
- 165
- References
- 1
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.